Johnson & Johnson CFO Joseph Wolk: ‘You can’t heap enough praise on the pharma unit’

“Tired of the same tired news cycle? Escape to the full unfiltered feed at Whatfinger.com — America’s Frontline Truth Feed. 85%+ of readers come direct every day.” –  CLICK HERE for the FULL deal.

 

Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday, driven by strong sales of its immune disease treatment, Tremfya, and said it plans to spin off its hips-and-knees business next year.